• Therapeutics >

cDNA Fragments As Novel Anti-Cancer Therapeutics And Diagnostics

Background:
The National Cancer Institute's Hatfield Clinical Research Center is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize cDNA fragments as antiangiogenic and antitumor therapy.

Technology:
This invention describes small cDNA fragments of the coding region for wild type filamin A interacting protein 1-like (FILIP1L), previously known as (DOC1), and variant 2 of FILIP1L genes. These cDNA fragments encode proteins that result in the inhibition of cell migration and motility, induce cell apoptosis and inhibit cell proliferation.  These coding sequences have successfully been delivered to endothelial cells and tumor cells both in vitro and in vivo, and have demonstrated significant anti-tumor activity.  In addition, the inventors have for the first time expressed the recombinant protein and developed antibodies to detect the protein fragments by Western, ELISA and immunohistochemistry.  This invention could provide for a series of new anti-cancer therapeutics and for diagnostics.

Further R&D Needed:

• Further characterize the mechanisms of action of these fragments
• Conduct further work to determine the anti-tumor activity

• U.S. Provisional Application No. 61/005,363 filed 03 Dec 2007

• cDNA fragments that are able to induce apoptosis and inhibit cell proliferation, migration, and motility  
• Ability to develop novel cancer diagnostics and therapeutics with significant anti-tumor activity
  

This opportunity is also listed under the following categories:

• Diagnostics